Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|October 2, 2018
Idifarma Now Offers Spray Drying for Highly Potent Drugs
Author(s)Pharmaceutical Technology Editors
Idifarma, a Spanish contract development and manufacturing organization (CDMO) that specialises in niche and highly potent products, confirmed on Oct. 1, 2018 that its good manufacturing practice (GMP) spray drying technology for highly potent drugs is now operational.
Idifarma, a Spanish contract development and manufacturing organization (CDMO) that specialises in niche and highly potent products, confirmed on Oct. 1, 2018 that its good manufacturing practice (GMP) spray drying technology for highly potent drugs is now operational.
The new equipment-GEA Niro Mobile Minor-has been installed and qualified in a dedicated area located at Idifarma’s European GMP plant, giving the company the capability to offer spray drying services for highly potent drugs up to category 4 OEL/OEB.
Commenting on the announcement, Luis Oquiñena, general manager and co-founder of Idifarma, stated in a
With this latest news in addition to prior investments in serialization and capsule filling capabilities, the company has strengthened its position as a niche CDMO in the field of development and manufacture of oral solid-dosage forms.
“We recently reported another successful inspection by Spanish authorities, which means Idifarma will continue to offer EU GMP manufacturing and analytical services to our clients,”
Idifarma will be exhibiting its products and services at CPhI Worldwide, Stand 8B70, on Oct. 9–11, 2018 in Madrid Spain.
Source:
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.